TRMLTourmaline Bio, Inc.

Nasdaq www.tourmalinebio.com


$ 14.37 $ -0.07 (-0.48 %)    

Tuesday, 14-May-2024 15:59:55 EDT
QQQ $ 445.89 $ 1.14 (0.26 %)
DIA $ 395.58 $ 1.12 (0.28 %)
SPY $ 523.16 $ 0.98 (0.19 %)
TLT $ 90.86 $ 0.25 (0.28 %)
GLD $ 218.12 $ 1.87 (0.86 %)
$ 14.44
$ 14.51
$ 0.00 x 0
$ 0.00 x 0
$ 14.37 - $ 14.77
$ 9.18 - $ 48.31
271,065
na
347.74M
$ 1.67
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-13-2024 03-31-2024 10-Q
2 03-19-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-14-2023 06-30-2023 10-Q
5 05-15-2023 03-31-2023 10-Q
6 03-31-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-15-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-17-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 06-14-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

HC Wainwright & Co. analyst Yi Chen reiterates Tourmaline Bio (NASDAQ:TRML) with a Buy and maintains $48 price target.

Core News & Articles

Truist Securities analyst Robyn Karnauskas reiterates Tourmaline Bio (NASDAQ:TRML) with a Buy and maintains $74 price target.

 why-factset-research-shares-are-trading-lower-by-around-5-here-are-other-stocks-moving-in-thursdays-mid-day-session

Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-th...

 dow-jumps-200-points-us-weekly-jobless-claims-fall

U.S. stocks traded higher this morning, with the Dow Jones index gaining around 200 points on Thursday. Following the market o...

 five-below-posts-q4-results-joins-lexinfintech-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session

U.S. stock futures were higher this morning, with the Dow futures gaining by around 100 points on Thursday.

Core News & Articles

HC Wainwright & Co. analyst Yi Chen reiterates Tourmaline Bio (NASDAQ:TRML) with a Buy and maintains $48 price target.

Core News & Articles

Tourmaline Bio (NASDAQ:TRML) reported quarterly losses of $(0.81) per share. This is a 85.3 percent increase over losses of $(5...

Core News & Articles

The gross proceeds to Tourmaline from the offering, before deducting underwriting discounts and commissions and offering expens...

Core News & Articles

Tourmaline Bio, Inc. ("Tourmaline") (NASDAQ:TRML), a late-stage clinical biotechnology company developing transformativ...

Core News & Articles

Tourmaline plans to accelerate the initiation of a pivotal Phase 3 trial in 2024 evaluating subcutaneous TOUR006 every 8 week...

 tdcx-receives-preliminary-non-binding-proposal-letter-joins-pure-storage-dyne-therapeutics-and-other-big-stocks-moving-higher-on-wednesday

U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. (NYSE: TDCX) r...

 why-aar-shares-are-trading-lower-by-7-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.

 karuna-therapeutics-jumps-following-takeover-by-bristol-myers-joins-rocket-lab-usa-altair-engineering-and-other-big-stocks-moving-higher-on-friday

U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (...

Core News & Articles

Jefferies analyst Roger Song initiates coverage on Tourmaline Bio (NASDAQ:TRML) with a Buy rating and announces Price Target...

Core News & Articles

Truist Securities analyst Robyn Karnauskas initiates coverage on Tourmaline Bio (NASDAQ:TRML) with a Buy rating and announce...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION